A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Renal Function

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506063-34-00

Acronym

209626 (DreaMM 12)

Enrollment

Registered

2024-01-26

Start date

2021-07-23

Completion date

Unknown

Last updated

2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/Refractory Multiple Myeloma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Greece

None listed

Source: EU CTIS · Data processed: Feb 4, 2026